Pfizer and BioNTech seek FDA authorization for 3-dose vaccine for children aged six months to five years, and WHO warns that fewer tests mean fewer cases detected

Pfizer Inc. and BioNTech SE have asked the U.S. Food and Drug Administration to authorize their three-dose vaccine for children aged six months to five years, in a move that could add roughly 19 million young children to the program.